The protozoan parasite Toxoplasma gondii is a ubiquitous human pathogen which has emerged as a leading opportunistic infection associated with AIDS. Clinical management of toxoplasmosis has traditionally relied on antifolates, but complications associated with the chronic therapy needed for immunodeficient patients have left us with no adequate treatment for this devastating disease. This proposal seeks to employ newly developed genetic and pharmacological tools to investigate drug sensitivity and resistance in Toxoplasma, focusing particularly on folate metabolism and the parasite's bifunctional dihydrofolate reductase-thymidylate synthase enzyme (DHFR-TS). Goals of this research include the development of improved treatment strategies for acute toxoplasmosis. Sequences and probes derived from the T. gondii DHFR-TS gene have been employed to examine the predicted structure of the enzyme in wild-type parasites, and to develop functional vectors for transient and stable molecular transformation of the parasite. Clinical cases of antifolate- resistant toxoplasmosis and similar mutants isolated in the lab will be screened for differences in sensitivity to combined pyrimethamine/sulfonamide treatment (in addition to sensitivity to pyrimethamine or sulfa alone), and examined for possible DHFR-TS mutations or altered gene expression. Mechanisms of DHFR-independent resistance will be identified by genetic means. DHFR-TS enzyme function will be assessed in transgenic parasites bearing mutations derived from four sources: naturally occurring allelic variation, mutations identified from drug- resistant laboratory strains and clinical isolates, modeling studies on the T. gondii enzyme, and point mutations thought to be associated with antifolate resistance in field isolates of the related parasite Plasmodium falciparum (malaria). Findings from this research will be combined with structure/function studies on the recombinant DHFR-TS enzyme, to assist in the design of novel antifolates with improved activity against the parasite. Because of the tremendous power of genetic techniques for the identification and analysis of drug targets, available transformation schemes will be modified to permit: (1) Targeted gene disruption and replacement, used in this context to examine mutations at the DHFR-TS locus; (2) Insertional mutagenesis and marker rescue, used to clone potential targets for therapeutic intervention and negative selectable markers for gene replacement studies; (3) Molecular cloning by complementation, focusing on DHFR-independent antifolate resistance genes which appear to be particularly important for pyrimethamine resistance in Toxoplasma; and (4) Optimal expression and overexpression of recombinant protein. In addition to their value for the analysis of folate metabolism and drug resistance, these tools should be broadly applicable to other studies on the biology and biochemistry of Toxoplasma.
| Shukla, Anurag; Olszewski, Kellen L; Llinás, Manuel et al. (2018) Glycolysis is important for optimal asexual growth and formation of mature tissue cysts by Toxoplasma gondii. Int J Parasitol 48:955-968 |
| Beiting, Daniel P; Hidano, Shinya; Baggs, Julie E et al. (2015) The Orphan Nuclear Receptor TLX Is an Enhancer of STAT1-Mediated Transcription and Immunity to Toxoplasma gondii. PLoS Biol 13:e1002200 |
| Lynch, Michael; Field, Mark C; Goodson, Holly V et al. (2014) Evolutionary cell biology: two origins, one objective. Proc Natl Acad Sci U S A 111:16990-4 |
| Beiting, Daniel P; Peixoto, Lucia; Akopyants, Natalia S et al. (2014) Differential induction of TLR3-dependent innate immune signaling by closely related parasite species. PLoS One 9:e88398 |
| Ouologuem, Dinkorma T; Djimdé, Abdoulaye A; Diallo, Nouhoum et al. (2013) Toxoplasma gondii seroprevalence in Mali. J Parasitol 99:371-4 |
| Klinger, Christen M; Nisbet, R Ellen; Ouologuem, Dinkorma T et al. (2013) Cryptic organelle homology in apicomplexan parasites: insights from evolutionary cell biology. Curr Opin Microbiol 16:424-31 |
| Hall, Aisling O'Hara; Beiting, Daniel P; Tato, Cristina et al. (2012) The cytokines interleukin 27 and interferon-? promote distinct Treg cell populations required to limit infection-induced pathology. Immunity 37:511-23 |
| Pszenny, Viviana; Davis, Paul H; Zhou, Xing W et al. (2012) Targeted disruption of Toxoplasma gondii serine protease inhibitor 1 increases bradyzoite cyst formation in vitro and parasite tissue burden in mice. Infect Immun 80:1156-65 |
| Beiting, Daniel P; Roos, David S (2011) A systems biological view of intracellular pathogens. Immunol Rev 240:117-28 |
| Fernández Robledo, José A; Caler, Elisabet; Matsuzaki, Motomichi et al. (2011) The search for the missing link: a relic plastid in Perkinsus? Int J Parasitol 41:1217-29 |
Showing the most recent 10 out of 38 publications
